Crystallization of a polymorphic hydrate system

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 753-763

  Tian, F ^a   Qu, H ^b   Louhi Kultanen, M ^c   Rantanen, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c LAPPEENRANTA UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Crystal structure; Crystallization; Hydrate; Nitrofurantoin; Polymorphism; Supersaturation

Indexed keywords

HYDROGEN; NITROFURANTOIN; NITROFURANTOIN HYDRATE I; NITROFURANTOIN HYDRATE II; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COOLING; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG SOLUBILITY; DRUG STRUCTURE; EVAPORATION; HYDRATION; HYDROGEN BOND;

EID: 74049124218     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21865     Document Type: Article

References (35)

1. Chow K, Tong HHY, Lum S, Chow AHL. 2008. Engineering of pharmaceutical materials: An industrial perspective. J Pharm Sci 97:2855-2877.
2. Gavezzotti A. 2007. A solid-state chemist's view of the crystal polymorphism of organic compounds. J Pharm Sci 96:2232-2241.
3. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid state chemistry of drugs. 2nd edition. West Lafayette, IN: SSCI Inc.
4. Brittain HG. 2009. Polymorphism and solvatomorphism 2007. J Pharm Sci 98: 1617-1642.
5. York P. 1983. Solid-state properties of powders in the formulation and processing of solid dosage forms. Int J Pharm 14:1-28.
6. Ostwald WZ. 1897. Studies on formation and transformation of solid materials. Z Phys Chem 22:289-330.
7. ter Horst JH, Kramer HJM, Jansens PJ. 2002. A new molecular modeling approach to predict concomitant nucleation of polymorphs. Cryst Growth Des 2:351-356.
8. Bernstein J, Davey RJ, Henck J-O. 1999. Concomitant polymorphs. Angew Chem Int Ed 38: 3440-3461.
9. Blagden N, Davey RJ. 2003. Polymorph selection: Challenges for the future? Cryst Growth Des 3:873-885.
10. Stoica C, Tinnemans P, Meekes H, Vlieg E, van Hoof PJCM, Kaspersen FM. 2005. Epitaxial 2D nucleation of metastable polymorphs: A 2D Version of Ostwald's Rule of Stages. Cryst Growth Des 5: 833-1308.
11. Chen S, Xi H, Yu L. 2005. Cross-nucleation between ROY polymorphs. J Am Chem Soc 127:17439-17444.
12. Desgranges C, Delhommelle J. 2006. Molecular mechanism for the cross-nucleation between polymorphs. J Am Chem Soc 128:10368-10369.
13. Mitchell C, Yu L, Ward MD. 2001. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates. J Am Chem Soc 123:10830-10839.
14. Yu L. 2003. Nucleation of one polymorph by another. J Am Chem Soc 125:6380-6381.
15. Haleblian JK, Koda RT, Biles JA. 1971. Isolation and characterization of some solid phases of fluprednisolone. J Pharm Sci 60:1485-1488.
16. Shefter E, Higuchi T. 1963. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J Pharm Sci 52:781-791.
17. Khankari RK. 1993. Physicochemical characterization and thermodynamic properties of nedocromil salt hydrates. PhD Thesis: University of Minnesota, Minneapolis, MN.
18. van Tonder EC, Maleka TSP, Liebenberg W, Song M, Wurster DE, de Villiers MM. 2004. Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates. Int J Pharm 269:417-432.
19. Pienaar EW, Caira MR, Lotter AP. 1993. Polymorphs of nitrofurantoin. I. Preparation and X-ray crystal structures of two monohydrated forms of nitrofurantoin. J Crystallogr Spectrosc Res 23: 739-744.
20. Aaltonen J, Strachan CJ, Pollanen K, Yliruusi J, Rantanen J. 2007. Hyphenated spectroscopy as a polymorph screening tool. J Pharm Biomed Anal 44:477-483.
21. Otsuka M, Teraoka R, Matsuda Y. 1992. Rotatingdisk dissolution kinetics of nitrofurantoin anhydrate and monohydrate at various temperatures. Pharm Res 9:307-311.
22. Kojima T, Yamauchi Y, Onoue S, Tsuda Y. 2008. Evaluation of hydrate formation of a pharmaceutical solid by using diffuse reflectance infrared Fourier-transform spectroscopy. J Pharm Biomed Anal 46:788-791.
23. Otsuka M, Teraoka R, Matsuda Y. 1990. Characterization of nitrofurantoin anhydrate and monohydrate, and their dissolution behaviors. Chem Pharm Bull 38:2667-2670.
24. WikströmH, Rantanen J, Gift AD, Taylor LS. 2008. Toward an understanding of the factors influencing anhydrate-to-hydrate transformation kinetics in aqueous environments. Cryst Growth Des 8: 2684-2693.
25. Caira MR, Pienaar EW, Loetter AP. 1996. Polymorphism and pseudopolymorphism of the antibacterial nitrofurantoin. Mol Cryst Liq Cryst Sci Technol Section A Mol Cryst Liq Cryst 279:241-264.
26. Otsuka M, Matsuda Y. 1993. Effect of environmental humidity on the transformation pathway of nitrofurantoin modifications during grinding and the physicochemical properties of ground products. J Pharm Pharmacol 45:406-413.
27. Kelly RC. 2003. A molecular approach to understanding the directed nucleation and phase transformation of carbamazepine and nitrofurantoin in aqueous and organic solutions. Ph.D Thesis, University of Michigan; MI, USA.
28. Nyvlt J. 1968. Kinetics of nucleation in solution. J Cryst Growth 3-4:377-383.
29. Tian F, Qu H, Louhi-Kultanen M, Rantanen J. 2009. Mechanistic insight into the evaporative crystallization of two polymorphs of nitrofurantoin monohydrate. J Cryst Growth 311: 2580-2589.
30. Beckmann W, Nickisch K, Budde U. 1998. Development of a seeding technique for the crystallization of the metastable a modification of abecarnil. Org Process Res Dev 2:298-304.
31. Beckmann W. 2000. Seeding the desired polymorph: Background, possibilities, limitations, and case studies. Org Process Res Dev 4:372-383.
32. Davey RJ, Williams-Seton L, Lieberman HF, Blagden N. 1999. Stabilizing a solid-solid interface with a molecular-scale adhesive. Nature 402:797-799.
33. Gracin S, Uusi-Penttilä M, Rasmuson ÅC. 2005. Influence of ultrasound on the nucleation of polymorphs of p-aminobenzoic acid. Cryst Growth Des 5:1787-1794.
34. Mersmann A. 2001. Crystallization Technology Handbook. 2nd edition. New York: Marcel Dekker.
35. Gillon AL, Feeder N, Davey RJ, Storey R. 2003. Hydration in molecular crystals-A Cambridge structural database analysis. Cryst Growth Des 3:663-673.